" class="no-js "lang="en-US"> Matthew Whitty - Medtech Alert
Wednesday, September 10, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Matthew Whitty

Matthew Whitty

About Matthew Whitty

Related Story

Fundraising

 SBRI Healthcare Awards £1 Million to Pioneering Innovations to Support the Delivery of a Net Zero NHS | Pharmtech Focus

SBRI Healthcare Awards £1 Million to Pioneering Innovations to Support the Delivery of a Net Zero NHS

January 27 2022

SBRI Healthcare has awarded a total of £1 million to ten pioneering MedTech and Digital […]

Artificial Intelligence

 £36 Million Boost for AI Technologies to Revolutionise NHS Care | Pharmtech Focus

£36 Million Boost for AI Technologies to Revolutionise NHS Care

June 16 2021

New technology will help detect cancers and provide mental health support Projects are part of […]